Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients.

Content Provider	Semantic Scholar
Author	Mastro, Lucia Del Catzeddu, Tiziana Boni, Luca Bell, Christopher Sertoli, Mario Roberto Bighin, Claudia Clavarezza, Matteo Testa, David Del Venturini, Marco
Copyright Year	2006
Abstract	BACKGROUND Standard methods to prevent chemotherapy-induced early menopause in young, breast cancer patients are unavailable to date. Preclinical data has suggested that luteinising hormone-releasing hormone (LH-RH) analogs given during treatment can decrease the gonado-toxicity induced by chemotherapy. This phase II study aimed to assess the activity of such a method in young, breast cancer patients undergoing adjuvant chemotherapy. PATIENTS AND METHODS Premenopausal patients received the LH-RH analog goserelin 3.6 mg every 4 weeks before and during chemotherapy. According to two-stage optimal phase II Simon design, treatment was considered clinically interesting if it was able to prevent menopause in 19 out of 29 patients of the study population. The resumption of ovarian function was defined by a resumption of menstrual activity or by a follicle-stimulating hormone (FSH) value < or = 40 IU/l within 12 months after the last cycle of chemotherapy. RESULTS Thirty patients were enrolled and 29 were evaluable. Median age was 38 years (range 29-47). All but one patient received CEF regimen (cyclophosphamide, epirubicin, 5-fluorouracil). Resumption of menstrual activity was observed in 21 patients (72%; 95% CI 52% to 87%) and a FSH value < or = 40 IU/l in 24 patients (83%; 95% CI 63% to 93%). Menses resumption was observed in 16 out of 17 patients (94%) with age <40 years and in five out of 12 patients (42%) with age > or = 40 years. CONCLUSION Goserelin given before and during chemotherapy may prevent premature menopause in the majority of patients. The different success rate by age, however, indicates the need of a prospective evidence of the efficacy of such a strategy.
Starting Page	935
Ending Page	946
Page Count	12
File Format	PDF HTM / HTML
Alternate Webpage(s)	https://oup.silverchair-cdn.com/oup/backfile/Content_public/Journal/annonc/17/1/10.1093/annonc/mdj029/2/mdj029.pdf?Expires=1492542952&Key-Pair-Id=APKAIUCZBIA4LVPAVW3Q&Signature=HDIfGRzF4R-Mms0qGmQN23WvhWNXXOUjZkwbMEI~0RWu0867b0WOTozEY9yeBtDLaTB0xAv~d-dES3Vc6kVfOWvaIsyO2nLMlWBKe9lBRTxUVqVvLvcWpiMIGIUzoQNPmFSs6AHS~WLpJYJ32iIofbQE7NZ4wjK~DN70Rd403UpNR6Y1fJ2lbdSFbzEg1MzU0OUYr6pnfMq3UK7Tqmu8hilgAcekeel4o3tzRALPmC6as9AePOx4Wu9pmvXpYiMTOcEN4Ux-Z9Vqht8cOf2KobwN6CWlDOrEaxJG9PQVizw8~dakeOFZaFxJBT3Z~rr3z72I5zqeSt5-whYp8R2sPg__
Alternate Webpage(s)	https://watermark.silverchair.com/mdj029.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAaMwggGfBgkqhkiG9w0BBwagggGQMIIBjAIBADCCAYUGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMxYmnrktlVgHD21S7AgEQgIIBVmX9TbQrkmMGfjPHJ-5lEm5zwwFNUvkXrmRMax9SgMu2lira7DLZ2hUaVM2CIWUhonN1yDEuRS-pbhxpDhApplHFzv7AjfYutERvci9CkHzfp8ZWklwhxQZMtDlYNUTIQ2Q52CqLDcTSr8l9DYDolnc5kTPeVWPgqg6_yeyM3FRz7KHarqBTwF0SP2dLRofaEKO8mnzm3-dTSGQRvVtMHCuSumBx6DYu_WZ7oIsjzeXdmi1IwWx_JCoSwbNRC00xh8_lrBX5Jg_E0ad5IyNuifmEV6MPNylKSlRmiyExGc4HwTqXn25-wG0097dZmPcok6Rhb9xbivunV9IpWNzqf_0ltHOxfXNRaJPvqt6jbOWpyh3gCkTNer4fBxig_6Yp3cPt0sw7i8TUbLT-8zOgamn4gWWrKUlssYyiNlZwuh7ds5WpLvl7RECa1soEcn4ADYATmYSb9A
PubMed reference number	16254024v1
Volume Number	17
Issue Number	1
Journal	Annals of oncology : official journal of the European Society for Medical Oncology
Language	English
Access Restriction	Open
Subject Keyword	Adverse reaction to drug Analog Chemotherapy, Adjuvant Cyclophosphamide Evaluable Disease FEC protocol Fluorouracil Gonadorelin Goserelin Mammary Neoplasms Menstruation Ovarian Follicle Patients Pharmaceutical Adjuvants Premature Menopause Stimulation (motivation) ovarian neoplasm
Content Type	Text
Resource Type	Article